Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

no longer respond to the standard of care under Fast Track designation from the U.S. Food and Drug Administration.

About Carcinoid Syndrome

Carcinoid syndrome is a chronic condition caused by metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. Patients with carcinoid syndrome currently have limited therapeutic options, and the standard of care includes chronic therapy with somatostatin analogues, which are delivered by injection. With current therapy, the gastrointestinal symptoms return over time in the vast majority of patients, hence the need for new agents.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), a ... to personalize and advance the treatment and management of ... Lucier as chairman of Epic,s board of directors. ... Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board of ... rare cell analysis platform with special focus on the ...
(Date:7/30/2014)... 30, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that their third ... the reduction of recurrence of hypertrophic scars ... initiated. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... To become better healers, tissue engineering need a timely and ... already are or can become the tissue they need to ... that the stiffness, viscosity, and other mechanical properties of adult ... predict whether they will turn into bone, cartilage, or fat. ...
... are not a condensed matter physicist, vanadium oxide (VO2) may ... metal. It,s an insulator. It,s a window coating and an ... at Rice University, scientists have a new way to reversibly ... the simplest substances -- hydrogen. So what is VO2? ...
... May 21, 2012   Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... families nationwide and internationally, today announced that revenues for the ... compared to $1.45 in the same period last year. The ...
Cached Biology Technology:Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3Reversible doping: Hydrogen flips switch on vanadium oxide 2Reversible doping: Hydrogen flips switch on vanadium oxide 3Cord Blood America Announces First Quarter Financial Results 2Cord Blood America Announces First Quarter Financial Results 3
(Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
(Date:7/30/2014)... they eat, the Food and Drug Administration (FDA) earlier ... label found on nearly every food product in the ... (C&EN), the weekly news magazine of the American ... fight that has ensued. , Britt Erickson, a senior ... Facts label has remained largely the same for two ...
(Date:7/30/2014)... a subject of major interest in neuroscience. A ... the distinct stages of Wallerian degeneration: transcription factor ... Although gene expression responses in the distal segment ... are known, differences in gene expression between the ... Yao and co-workers from Nantong University, China used ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... fruit trees in the world. Citrus has a long history ... Until now, however, the exact genetic origins of cultivated citrus ... C. limon ), and grapefruit ( C. paradisi ) have ... published a study in the Journal of the American Society ...
... , ,Mathematical models continue to play a major ... and control of malaria, a life-threatening parasitic disease ... Although existing models have advanced our understanding of ... new challenges., The National Institute for Mathematical and ...
... what happened to the dinosaurs, and he or she will ... ask how dinosaurs rose to prominence and you,ll likely get ... say about the subject. But now, as EARTH explores in ... revealing the backstory of the rise of dinosaurs. Learn ...
Cached Biology News:Genetic origin of cultivated citrus determined 2Malaria modeling and control focus of workshop 2
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... MOISTURE. Protein synthesis inhibitor. Inhibits translation ... polypeptide chains. Induces DNA fragmentation in ... cells. Purity: ≥98% by TLC. ...
... Stabilizer is a bovine protein-free alternative ... is an aqueous solution that contains ... buffer (3-(N-Morpholino) propanesulfonic acid), pH 6.0 ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... quantitation kit is used to quantitate double-stranded DNA ... RNA or protein. With this kit, DNA is ... detected with a VersaFluor or other fluorometer. The ... ng per ml to 5 micrograms per ml ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
Biology Products: